Meet the Systane® Family - Designed for All Dry Eye Needs
Explore the Systane® family of products with specially designed formulations for all types of patients’ Dry Eye needs. Find the Systane® solution that is right for your patient, depending on their symptoms and underlying causes. Also, learn more about Systane® proprietary HP-Guar intelligent delivery system.
HP-Guar Technology
Hydroxypropyl-guar or HP-Guar acts as a gelling agent, creating an elastic matrix on the corneal surface upon installation, producing a protective environment and forming a bio-adhesive gel that binds specifically to the hydrophobic regions of the cornea, where integrity is compromised.1
Benefits of HP-Guar include:
- Increased retention1,2
- Prolonged protection1,2
- Greater hydration and lubrication compared to Hyaluronic Acid alone1,2*
*In vitro data
For Evaporative Dry Eye
As the name suggests, tears evaporate too quickly but lacrimation (watering) is normal.4,5 One of the leading causes is Meibomian Gland Dysfunction (MGD).4,5
For Aqueous Deficient Eye
Aqueous Deficient Dry Eye indicates Dry Eye as a result of a lacrimal gland tear secretion defect.
Essentially, the lacrimal gland doesn't produce enough tear fluid.4,5
References:
1. Springs CL. Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye. Adv Ther. 2010;27(10):681-690.
2. Rangarajan R, Kraybill B, Ogundele A, Ketelson H. Effects of a Hyaluronic Acid/Hydroxypropyl Guar Artificial Tear Solution on Protection, Recovery, and Lubricity in Models of Corneal Epithelium. J. Ocul. Pharmacol. Ther. 2015;31(8):491-497.
3. Silverstein S, Yeu E, Tauber J, et al. Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial. Clin Ophthalmol. 2020;14:3167-3177.
4. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472–478.
5. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report [published correction appears in Ocul Surf. 2019 Oct;17(4):842]. Ocul Surf. 2017;15(3):438-510.
See instructions for use, precautions, warnings and contraindications
Exclusive Use For Health Care Professionals